Patients with bullous pemphigoid treated with Dupixent maintained disease control and symptom relief, according to phase 2/3 trial results released by Regeneron and Sanofi.The randomized, double ...

Bullous Pemphigoid Causes. Bullous pemphigoid is an autoimmune disease, which means something causes your immune system to attack your body’s cells.But researchers don’t know why this happens ...

Patients with bullous pemphigoid experienced symptom improvement with dupilumab treatment, according to a study.“Bullous pemphigoid (BP) is one of the most common autoimmune bullous diseases ...

A decision on the bullous pemphigoid indication is expected on June 20, 2025. References: Press release: Dupixent sBLA approved for FDA priority review for the targeted treatment of bullous ...

Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial ...

Get Instant Summarized Text (Gist) Dupixent (dupilumab) has received FDA approval for treating adults with bullous pemphigoid. In clinical trials, Dupixent led to higher rates of sustained disease ...

Recent studies highlight the potential pathophysiology and presentation of immune checkpoint inhibitor–associated cutaneous adverse events, including bullous pemphigoid and lipodystrophy.